Revised Outcome of the Board Meeting dated 30.05.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has reported its audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, along with a 7% final dividend recommendation (Re. 0.70 per share on Rs. 10 face value). Standalone revenue grew strongly to Rs. 45,626.82 lakhs from Rs. 34,907.18 lakhs, up about 30.7% YoY. Standalone profit after tax rose to Rs. 2,080.76 lakhs from Rs. 1,562.34 lakhs, a jump of around 33% YoY, with basic EPS at Rs. 44.83 (vs Rs. 33.32). The consolidated FY25 PAT was Rs. 1,973.93 lakhs, lower than standalone because the newly acquired step-down subsidiary One Pet Stop posted a loss of Rs. 173.18 lakhs. The auditor (R.H. Nisar & Co.) issued an unmodified opinion on both standalone and consolidated results. However, the auditor flagged a delay in transferring unclaimed dividends and corresponding shares to the IEPF for FY16 and FY17 as an 'Other Matter.'
Strong topline and bottomline growth with a modest dividend is a positive signal for shareholders, but the significantly negative operating cash flow (Rs. -2,888.33 lakhs vs Rs. -43.87 lakhs last year) and rising short-term borrowings suggest working capital stress and increased reliance on debt. The IEPF compliance lapse is a minor governance red flag worth tracking.